<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125904</url>
  </required_header>
  <id_info>
    <org_study_id>A8081018</org_study_id>
    <nct_id>NCT01125904</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers</brief_title>
  <official_title>A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of Crizotinib Oral Liquid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being
      tested for its' palatability in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Taste assessment of new formulation. Subjects will not ingest the drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A complete description of the sensory attributes of drug product prototype formulations (eg, aroma, flavor, texture, and mouthfeel).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>crizotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.</description>
    <arm_group_label>crizotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female of non childbearing potential subjects between the ages of
             18 and 75 years, inclusive.

          -  Subjects must be trained sensory panelists.

          -  An informed consent document signed and dated by the subject or a legally acceptable
             representative.

          -  Subjects who are willing and able to comply with scheduled visits, product
             evaluations, laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  A history of clinically significant hematological, renal, endocrine, pulmonary ,
             glaucoma, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic
             disease (excluding untreated, asymptomatic seasonal allergies at the time of product
             evaluation) as evaluated through a medical history.

          -  A history of hypersensitivity to any inactive ingredients employed in the
             formulation(s).

          -  Receiving treatment with an investigational drug within 28 days preceding any of the
             product evaluations for this study.

          -  Participation in a product taste evaluation (ie, 'sip and spit' type taste evaluation)
             involving an active pharmaceutical ingredient (API) within 5 half lives of that API.

          -  Unwilling or unable to comply with the Lifestyle guidelines described in this
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081018&amp;StudyName=A%20Study%20To%20Investigate%20The%20Taste%20Of%20Crizotinib%20Liquid%20In%20Trained%20Healthy%20Adult%20Volunteers%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Crizotinib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

